Phathom Pharmaceuticals, Inc. (PHAT)
收市後：
| 前收市價 | 10.69 |
| 開市 | 10.72 |
| 買盤 | 10.47 x 100 |
| 賣出價 | 10.64 x 100 |
| 今日波幅 | 10.25 - 10.73 |
| 52 週波幅 | 6.07 - 17.02 |
| 成交量 | |
| 平均成交量 | 802,319 |
| 市值 | 616.961M |
| Beta 值 (5 年，每月) | 0.67 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -4.46 |
| 業績公佈日 | 2024年8月08日 - 2024年8月12日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 22.88 |
Insider MonkeyPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2024 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2024 Earnings Call Transcript May 11, 2024 Phathom Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello, and welcome to Phathom Pharmaceuticals First Quarter 2024 Earnings Results Call. [Operator Instructions] Please be advised […]
InvestorPlaceThe 3 Best Healthcare Stocks to Buy in May 2024
Healthcare is a basic human need that can withstand economic downturns. Indeed, this important endeavor receives a huge amount of funds in developed countries globally and the West in particular. Roughly $8.3 trillion annually is devoted to global healthcare, and nearly 50% of that amount is spent in the U.S. Moreover, healthcare spending is increasing meaningfully faster than global GDP. Meanwhile, American firms are always developing lucrative drugs, medical devices and other medical technolog
ZacksPhathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Lags Revenue Estimates
Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of 0.70% and 30.73%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
